MVT-5873 clinical trials
Also written MVT-5873 and HuMab-5B1.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2016
How each study uses MVT-5873 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
4 studies that test it; most in 2016 (1)
| Year | Studies |
|---|---|
| 2016 | 1 |
| 2017 | 1 |
| 2019 | 1 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 1
BioNTech Research & Development, Inc. (2) · National Cancer Institute (NCI) (1) · BioNTech SE (1)
Often tested with
Tested in the same studies.
MVT-1075 (1)
Studies
Open first, then newest update. How each study uses MVT-5873 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 4
- Safety, Tolerability, and Efficacy of mFOLFIRINOX ± BNT321 as Adjuvant Therapy Following Curative Resection in Patients With Pancreatic AdenocarcinomaTerminatedPhase 1/2BioNTech SENCT06069778Written as BNT321 0.5 mg/kg
- Study of HuMab-5B1 (MVT-5873) in Subjects With Pancreatic Cancer or Other Cancer Antigen 19-9 (CA19-9) Positive MalignanciesTerminatedPhase 1BioNTech Research & Development, Inc.NCT02672917Written as MVT-5873
- Study of 177Lu Human Monoclonal Antibody 5B1 (MVT-1075) in Combination With a Blocking Dose of MVT-5873 as RadioimmunotherapyTerminatedPhase 1BioNTech Research & Development, Inc.NCT03118349Written as MVT-5873
- Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal CancersCompletedPhase 2National Cancer Institute (NCI)NCT03801915Written as MVT-5873
Given beside what is tested · 2 — MVT-5873 is usual care or a partner of the new treatment
Codes
What other systems call MVT-5873 · ClinicalTrials.gg INT017059
- UNII (FDA) KEX1QY18OHMVT-5873One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | KEX1QY18OH | MVT-5873 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.